

AMENDMENT

In the Claims:

Please cancel claim 49 without prejudice or disclaimer.

Please replace claim 48 with the following claim 48:

48. (Amended) A method to identify an agent that decreases the expression status of 101P3A11 protein, which method comprises:

providing cells that express 101P3A11 protein;

contacting a first sample of said cells with a candidate compound under conditions

wherein the expression status of the 101P3A11 protein is observable;

observing said contacted cells for at least one property characteristic of said expression status of said 101P3A11 protein;

observing a second sample of said cells which have not been contacted with said candidate compound for said at least one property characteristic of the expression status of the 101P3A11 protein;

comparing the observed property in said first and second sample;

whereby a diminution in the property exhibited by said first sample as compared to said second sample identifies said compound as an agent that decreases the expression status of 101P3A11 protein.

Please add the following new claims 51 and 52:

51. (new) The method of claim 48 wherein the observing steps are carried out by

observing:

promotion of colony formation in soft agar and said property is a multiplicity of colonies;

or

invasion and metastasis of cancer cells and the property is invasive activity in an assay for invasive activity using a basement membrane or analog thereof; or

alteration of the cell cycle and the property is activity in the BrdU assay; or

Sub D

mediation of ERK phosphorylation by FBS, LPA, GRP or PAF and the property is presence or increase of phosphorylated ERK; or

activation of p38 and the property is presence or increase of phosphorylated p38; or phosphorylation of tyrosine and the property is presence or increase of phosphorylated tyrosine; or

effecting cell growth and said property is enhanced cell growth; or promotion of cell survival and said property is enhanced cell survival.

C₂

52. (new) The method of claim 48 wherein the observing steps are carried out by observing:

immunohistochemical analyses, and the property is alteration of 101P3A11 peptide sequence, alteration of 101P3A11 peptide localization, altered levels of 101P3A11 peptide expression, or altered association of 101P3A11 peptide association with polypeptide binding partners; or

Western blot analyses, and the property is alteration of 101P3A11 peptide sequence, alteration of 101P3A11 peptide localization, altered levels of 101P3A11 peptide expression, or altered association of 101P3A11 peptide association with polypeptide binding partners; or

Northern analyses, and the property is altered levels of expression of 101P3A11 RNA or alterations of 101P3A11 RNA; or

Southern analyses and the property is perturbations of the 101P3A11 DNA; or,

RT-PCR, and the property is altered levels of expression of 101P3A11 RNA or alterations of 101P3A11 RNA